1.Rituximab-CHOP Induced Interstitial Pneumonitis in Patients with Disseminated Extranodal Marginal Zone B Cell Lymphoma.
Kwang Min KIM ; Ho Cheol KIM ; Kyung Nyeo JEON ; Hoon Gu KIM ; Jung Hun KANG ; Jong Ryeal HAHM ; Gyeong Won LEE
Yonsei Medical Journal 2008;49(1):155-158
A 69-year-old male was diagnosed in February 2004 with stage IV extranodal marginal zone B cell lymphoma involving the mediastinal nodes, lung parenchyma and bone marrow with high LDH. Shortness of breath developed following the 5th course of Rituximab-CHOP chemotherapy (cyclophosphamide, Vincristine, Doxorubicin, Prednisolone). Bronchoscopy guided transbronchial lung biopsy revealed interstitial thickening and type II pneumocyte activation, compatible with interstitial pneumonitis. After treatment with prednisolone a complete resolution of the dyspnea was observed. The patient was well on routine follow-up at the outpatient clinic, with no progression of lymphoma or interstitial pneumonitis.
Aged
;
Antibodies, Monoclonal/*adverse effects/*therapeutic use
;
Antineoplastic Combined Chemotherapy Protocols/*adverse effects/*therapeutic use
;
Biopsy
;
Cyclophosphamide/adverse effects/therapeutic use
;
Doxorubicin/adverse effects/therapeutic use
;
Humans
;
Lung Diseases, Interstitial/*chemically induced/*pathology/radiography/surgery
;
Lymphoma, B-Cell, Marginal Zone/*drug therapy
;
Male
;
Prednisone/adverse effects/therapeutic use
;
Tomography, X-Ray Computed
;
Vincristine/adverse effects/therapeutic use